CorMedix completes $300M acquisition of Melinta; raises FY2025 revenue guidance

CorMedix Inc.

Acquisition closed Aug 29, 2025; $260M cash + $40M equity upfront, plus up to $25M in milestone payments.
Pro forma 2025 revenue guidance raised to $325-350M; synergies expected $35-45M annually.
Transaction expected near-term accretive to EPS with double-digit accretion in 2026.
Susan Blum appointed CFO, Elizabeth Hurlburt COO, Matthew David CBO effective immediately.
Contingent payments include tiered royalties on REZZAYO US net sales and low-single-digit royalties on MINOCIN US net sales.

item 1.01item 2.01item 3.02item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.